How to Get Evenity (Romosozumab) in West Virginia

What Evenity Is and Why Access Matters in West Virginia

Romosozumab (brand name Evenity) is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, romosozumab simultaneously stimulates new bone formation and reduces bone resorption, a dual mechanism unique among osteoporosis therapies [1]. The FDA approved Evenity in April 2019 for postmenopausal women with osteoporosis at high risk for fracture.

Why West Virginia Faces Unique Barriers

West Virginia has the oldest median population east of the Mississippi and among the highest osteoporotic fracture rates in the country. Rural geography concentrates most bone-health specialists in Charleston, Morgantown, and Huntington, leaving patients in southern coalfield counties and the Eastern Panhandle hours from a prescribing clinic. State Medicaid does not cover Evenity, which eliminates a coverage pathway available in roughly 30 other states.

The Clinical Case for Early Access

In the ARCH trial (N=4,093), romosozumab reduced new vertebral fractures by 48% compared with alendronate at 24 months and lowered clinical fractures by 27% during the first 12-month treatment phase [2]. These results make timely access a clinical priority for high-risk patients, not an elective convenience.

Who Can Prescribe Evenity in West Virginia

Any physician (MD or DO) licensed in West Virginia can prescribe romosozumab. The drug does not carry a REMS restriction. Nurse practitioners and physician assistants with prescriptive authority under WV Board of Medicine or Board of Osteopathic Medicine oversight may also prescribe it, though some payers require the ordering provider to hold a specialty credential in endocrinology, rheumatology, or orthopedics for prior authorization approval.

Specialist vs. Primary Care Prescribing

Most commercial insurers and Medicare Administrative Contractors (MACs) accept prescriptions from any licensed prescriber, but denials are more common when the ordering clinician is a family medicine physician without documented osteoporosis management history. If your PCP is willing to prescribe, ask them to include their bone-health management notes in the prior authorization packet.

Telehealth Prescribing Rules

West Virginia permits telehealth prescribing for Evenity. The state adopted permanent telehealth parity legislation in 2021, allowing providers licensed in WV to evaluate, diagnose, and prescribe via synchronous audio-video visits. A telehealth clinician can order the required labs, submit prior authorization, and coordinate with a local infusion center or specialty pharmacy for administration. The prescriber must hold an active WV medical license or be covered under an interstate compact.

Required Labs Before Starting Romosozumab

Evenity's prescribing information and most payer protocols require baseline laboratory evaluation before the first injection. Missing labs are the single most common reason for prior authorization delays.

Mandatory Baseline Panel

• Serum calcium (corrected for albumin). Romosozumab is contraindicated in patients with hypocalcemia until levels are corrected [1].
• 25-hydroxyvitamin D. Levels below 30 ng/mL should be repleted before initiation. The Endocrine Society recommends a target of 40 to 60 ng/mL for patients starting anabolic bone therapy [3].
• Estimated GFR or serum creatinine. Severe renal impairment (eGFR <30 mL/min) alters calcium homeostasis and increases hypocalcemia risk.
• DXA scan within 24 months. T-score documentation at the lumbar spine or femoral neck is required for every prior authorization submission. Most payers require a T-score of -2.5 or worse, or a history of fragility fracture.

Additional Tests Some Payers Require

Certain WV commercial plans and Medicare MACs also request a complete metabolic panel (CMP), serum phosphorus, and a FRAX score printout. Gathering all of these before submission prevents the back-and-forth that can add 2 to 4 weeks to the approval timeline.

The Prior Authorization Process in West Virginia

Nearly every payer covering Evenity in West Virginia requires prior authorization. The drug's average wholesale price exceeds $22,000 for a 12-month course, so insurers gate access behind clinical criteria.

Standard Documentation Checklist

A complete PA submission typically includes:

1. DXA scan report showing a T-score of -2.5 or lower at the spine, femoral neck, or total hip
2. Fragility fracture documentation (radiology report, ICD-10 codes) if the indication is fracture-based rather than T-score-based
3. Lab results for calcium, vitamin D, and renal function dated within 90 days
4. Treatment history showing failure of, intolerance to, or contraindication for at least one prior osteoporosis therapy (most payers require trial of a bisphosphonate or denosumab first)
5. Cardiovascular risk statement confirming the patient had no MI or stroke within the preceding 12 months (the FDA boxed warning drives this requirement)
6. Letter of medical necessity from the prescribing clinician, especially when the patient does not meet step-therapy criteria

Timeline Expectations

Initial PA decisions in WV typically arrive within 5 to 15 business days for commercial plans and 7 to 14 days for Medicare Part B. If denied, an appeal with supporting clinical notes and trial citations, particularly the ARCH data, can reverse roughly 40% to 60% of first-line denials according to specialty pharmacy industry benchmarks [4].

Peer-to-Peer Review Tips

When a PA is denied, the prescriber can request a peer-to-peer call with the payer's medical director. Dr. Andrea Singer, former president of the National Osteoporosis Foundation, has noted: "Clinicians should emphasize that romosozumab is a time-limited, 12-dose therapy with a defined stopping point, which distinguishes it from indefinite bisphosphonate use and can reduce long-term treatment costs."

Insurance Coverage Pathways for WV Residents

Coverage varies sharply depending on payer type. Here is a breakdown of the primary pathways available.

Medicare Part B

Evenity is a physician-administered injectable, so it falls under Medicare Part B (medical benefit) rather than Part D (pharmacy benefit). Medicare covers 80% of the allowed amount after the annual Part B deductible. Patients with a Medigap plan or Medicare Advantage plan may have lower out-of-pocket costs. The MAC serving West Virginia (Palmetto GBA for Jurisdiction M) processes claims under HCPCS code J3111.

Commercial Insurance

Most large commercial insurers in WV, including Highmark Blue Cross Blue Shield (the state's largest commercial carrier), The Health Plan, and UnitedHealthcare, cover Evenity with prior authorization. Step-therapy requirements vary: Highmark typically requires documentation of bisphosphonate trial or contraindication, while some UHC plans accept a FRAX major osteoporotic fracture probability exceeding 20% as standalone justification [5].

WV Medicaid

West Virginia Medicaid does not cover Evenity as of May 2026. Patients on Medicaid who meet clinical criteria may pursue an exception-to-policy (ETP) request, though approval rates are low. The more reliable alternative is the manufacturer's patient assistance program.

Manufacturer Assistance: Amgen Assist 360

Amgen's patient support program provides free Evenity to uninsured or underinsured patients with household incomes at or below 300% of the federal poverty level. For commercially insured patients, the Evenity copay card can reduce out-of-pocket costs to as low as $5 per injection, with a maximum annual benefit of $15,000. Medicare patients are not eligible for copay cards under federal anti-kickback statute rules, but may qualify for assistance through independent charitable foundations such as the HealthWell Foundation or the Patient Access Network Foundation.

Pharmacy and Administration Options in West Virginia

Romosozumab is not a self-injectable drug for most patients. Each monthly dose requires two separate 105 mg/1.17 mL prefilled syringes injected subcutaneously, typically in the abdomen, thigh, or upper arm. Administration usually takes place in a clinical setting.

Specialty Pharmacy Dispensing

Evenity is distributed through specialty pharmacies. In WV, major specialty pharmacy networks with local partnerships include CVS Specialty, Optum Specialty, and Biologics by McKesson. The specialty pharmacy ships the drug to the administering provider's office or, in some cases, directly to the patient with cold-chain packaging.

Infusion Centers and Clinic Administration

Patients in Charleston can receive injections at CAMC's osteoporosis clinic or WVU Medicine's endocrinology offices in Morgantown. For rural patients, some primary care offices will administer the injection if the specialty pharmacy delivers the product to the clinic. Confirm with your prescriber's office that they have a buy-and-bill arrangement or can accept specialty pharmacy shipments before the first dose.

503A Compounding Pharmacies

While West Virginia has licensed 503A compounding pharmacies, romosozumab is a biologic monoclonal antibody. Biologics cannot be replicated through standard compounding processes. No 503A pharmacy in the U.S. Compounds romosozumab. Patients should obtain the branded product exclusively from authorized specialty pharmacy channels.

Telehealth Workflow: Step-by-Step for WV Patients

Telehealth removes the geographic barrier that keeps many rural WV residents from seeing a bone-health specialist. Here is the typical workflow from first visit to first injection.

Step 1: Initial Telehealth Consultation

Schedule a video visit with a licensed endocrinologist or rheumatologist offering telehealth in WV. During this visit, the clinician will review your fracture history, DXA results, current medications, and cardiovascular risk profile. If you do not have a recent DXA scan, the provider will order one at a local imaging center.

Step 2: Lab Orders

The prescriber sends lab orders electronically to a WV laboratory (LabCorp and Quest both operate draw sites across the state, including in smaller cities like Beckley, Parkersburg, and Wheeling). Results typically return within 2 to 3 business days.

Step 3: Prior Authorization Submission

Once labs confirm eligibility and the DXA meets threshold criteria, the prescriber's office submits the PA. Turnaround: 5 to 15 business days for most payers.

Step 4: Specialty Pharmacy Coordination

After PA approval, the specialty pharmacy contacts the patient to confirm shipping details, copay responsibility, and delivery date. The pharmacy ships the drug in temperature-controlled packaging to the administering clinic.

Step 5: Monthly Injections

The patient receives 12 monthly injections at a local clinic. Some telehealth providers coordinate with the patient's PCP or a home health nurse for administration. Follow-up telehealth visits occur at months 3, 6, and 12 to monitor for adverse effects and plan the transition to antiresorptive therapy (typically denosumab or a bisphosphonate) after the 12-dose course.

Cardiovascular Safety Considerations

Evenity carries an FDA boxed warning for increased risk of major adverse cardiovascular events (MACE). In the ARCH trial, the romosozumab group experienced a higher rate of serious cardiovascular events compared with alendronate (2.5% vs. 1.9%) during the first 12 months [2]. The American Association of Clinical Endocrinology (AACE) recommends against prescribing romosozumab in patients who have had a myocardial infarction or stroke within the preceding year [6].

Pre-Treatment Cardiovascular Screening

Before prescribing, clinicians should assess baseline cardiovascular risk. This includes reviewing blood pressure, lipid panel, smoking status, and personal or family history of MI or stroke. Patients with uncontrolled hypertension (systolic BP consistently above 160 mmHg) or recent acute coronary syndrome should pursue alternative anabolic therapies such as teriparatide or abaloparatide.

Monitoring During Treatment

The Endocrine Society's 2020 guideline on pharmacological management of osteoporosis recommends reassessing cardiovascular symptoms at each monthly visit during the 12-dose course [7]. Patients should report new chest pain, sudden weakness, or speech difficulty immediately.

Transitioning After 12 Doses

Romosozumab is approved for a maximum of 12 monthly doses. Bone mineral density gains begin to decline within months of stopping treatment unless followed by an antiresorptive agent.

Evidence for Sequential Therapy

The FRAME extension study demonstrated that women who transitioned from romosozumab to denosumab continued to gain BMD at the lumbar spine (total increase of 11.3% from baseline at 24 months), while those switched to placebo lost a significant portion of the gains [8]. The Endocrine Society recommends initiating an antiresorptive within one month of the final romosozumab dose.

Practical Sequencing in WV

Most WV prescribers transition patients to denosumab (Prolia) every 6 months or to oral alendronate 70 mg weekly. The choice depends on patient preference, renal function, and insurance coverage. Denosumab requires its own prior authorization in WV but has broader Medicaid coverage than romosozumab.

Cost Field Without Insurance

A single month's supply of Evenity (two prefilled syringes) carries a wholesale acquisition cost of approximately $1,825 per dose, totaling roughly $21,900 for the full 12-dose course. Without insurance, patients should contact Amgen Assist 360 directly at 1-844-633-6489. Eligible patients receive the drug at no cost. For patients whose income exceeds the 300% FPL threshold but who still face high out-of-pocket costs, working with a specialty pharmacy benefits investigator can identify plan-specific copay caps or accumulator adjustment workarounds.

The Amgen Safety Net Foundation, a separate entity from Amgen Assist 360, may cover patients who fall outside standard eligibility but have documented financial hardship. Application processing takes 2 to 4 weeks [9].